Skip to main content
. 2022 Jul 11;146(6):450–462. doi: 10.1161/CIRCULATIONAHA.122.059150

Figure 3.

Figure 3.

Changes in plasma renin concentration, urine 8-isoprostane, and urine cyclic guanosine monophosphate during screening subtracted from randomization and placebo subtracted from empagliflozin in patients with type 1 diabetes at baseline and in response to ramipril treatment after addition of empagliflozin or placebo. Changes in (A) plasma renin concentration, (B) urine 8-isoprostane, and (C) urine cyclic guanosine monophosphate during screening subtracted from randomization and placebo subtracted from empagliflozin in patients with type 1 diabetes at baseline and in response to ramipril treatment after addition of empagliflozin or placebo.